Evaluation of two xenobiotic reductases from Pseudomonas putida for their suitability for magnetic nanoparticle‐directed enzyme prodrug therapy as a novel approach to cancer treatment

Evaluating the abilities of diverse nitroaromatic prodrug metabolites to exit a model Gram negative vector for bacterial-directed enzyme-prodrug therapy

(2018) Jasmine V.E. Chan-Hyams et al.   BIOCHEMICAL PHARMACOLOGY

Time dependent HPLC analysis of the product ratio of enzymatically reduced prodrug CB1954 by a modified and immobilised nitroreductase

(2018) Patrick Ball et al.   EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES

Nitroreductase gene-directed enzyme prodrug therapy: insights and advances toward clinical utility

(2015) E. M. Williams et al.   BIOCHEMICAL JOURNAL

Identification of novel nitroreductases from Bacillus cereus and their interaction with the CB1954 prodrug

(2015) Vanessa V. Gwenin et al.   BIOCHEMICAL PHARMACOLOGY

Creation and screening of a multi-family bacterial oxidoreductase library to discover novel nitroreductases that efficiently activate the bioreductive prodrugs CB1954 and PR-104A

(2013) Gareth A. Prosser et al.   BIOCHEMICAL PHARMACOLOGY

The Role of Bystander Effects in the Antitumor Activity of the Hypoxia-Activated Prodrug PR-104

(2013) Annika Foehrenbacher et al.   Frontiers in Oncology

A phase I trial of PR-104, a pre-prodrug of the bioreductive prodrug PR-104A, given weekly to solid tumour patients

(2011) Mark J McKeage et al.   BMC CANCER

Colloidal Gold Modified with a Genetically Engineered Nitroreductase: Toward a Novel Enzyme Delivery System for Cancer Prodrug Therapy

(2011) Vanessa V. Gwenin et al.   LANGMUIR

The Bioreductive Prodrug PR-104A Is Activated under Aerobic Conditions by Human Aldo-Keto Reductase 1C3

(2010) C. P. Guise et al.   CANCER RESEARCH

Characterization of xenobiotic reductase A (XenA): study of active site residues, substrate spectrum and stability

(2010) Yanto Yanto et al.   CHEMICAL COMMUNICATIONS

Balancing the efficacy and toxicity of chemotherapy in colorectal cancer

(2010) Michael S. Braun et al.   Therapeutic Advances in Medical Oncology

E. coli NfsA: an alternative nitroreductase for prodrug activation gene therapy in combination with CB1954

(2009) S O Vass et al.   BRITISH JOURNAL OF CANCER

DNA Cross-Links in Human Tumor Cells Exposed to the Prodrug PR-104A: Relationships to Hypoxia, Bioreductive Metabolism, and Cytotoxicity

(2009) R. S. Singleton et al.   CANCER RESEARCH

A Phase I/II Clinical Trial in Localized Prostate Cancer of an Adenovirus Expressing Nitroreductase with CB1984

(2009) Prashant Patel et al.   MOLECULAR THERAPY

Nitroreductase from Bacillus licheniformis : A stable enzyme for prodrug activation

(2008) Caroline D. Emptage et al.   BIOCHEMICAL PHARMACOLOGY

Hormesis defined

(2007) Mark P. Mattson   AGEING RESEARCH REVIEWS

Prodrug Strategies in Anticancer Chemotherapy

(2007) Felix Kratz et al.   ChemMedChem